Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Shares		Common Stock and Capital Surplus	[2]	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022				1,758
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022	[1]				(458)
Balance at beginning of period at Dec. 31, 2022		$ 71,769	$ 71,469		$ (31,858)	[1]	$ 48,193		$ 56,398	$ (1,264)	$ 300
Shareholders' Equity [Roll Forward]
Net income		2,142	2,136						2,136		6
Other comprehensive income (loss)		389	389							389
Stock option activity, stock awards and other (in shares)				1
Stock option activity, stock awards and other		122	122				122
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(22)
Purchase of treasury shares, net of ESPP issuances		(1,962)	(1,962)		$ (1,944)	[1]	(18)
Common stock dividends		(781)	(781)						(781)
Other increases (decreases) in noncontrolling interests		(99)	9				9				(108)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2023				1,759
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2023	[1]				(480)
Balance at end of period at Mar. 31, 2023		$ 71,580	71,382		$ (33,802)	[1]	48,306		57,753	(875)	198
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023		(480)			(480)	[1]
Balance at beginning of period at Dec. 31, 2023		$ 76,636	76,461		$ (33,838)	[1]	48,992		61,604	(297)	175
Shareholders' Equity [Roll Forward]
Net income		1,124	1,113						1,113		11
Other comprehensive income (loss)		(44)	(44)							(44)
Stock option activity, stock awards and other (in shares)				3
Stock option activity, stock awards and other		244	244				244
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(39)
Purchase of treasury shares, net of ESPP issuances		(2,962)	(2,962)		$ (2,935)	[1]	(27)
Common stock dividends		(844)	(844)						(844)
Other increases (decreases) in noncontrolling interests		$ (4)									(4)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2024				1,771
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2024		(519)			(519)	[1]
Balance at end of period at Mar. 31, 2024		$ 74,150	$ 73,968		$ (36,773)	[1]	$ 49,209		$ 61,873	$ (341)	$ 182

[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of March 31, 2024 and 2023 and December 31, 2023 and 2022.

[2] Common stock and capital surplus includes the par value of common stock of $18 million as of March 31, 2024 and 2023 and December 31, 2023 and 2022.